Neurotrophic keratitis acquires recombinant nerve growth factor therapy
Cenegermin (recombinant nerve growth factor) maturity, follow-on programs, and structured corneal-care pathways are reshaping neurotrophic keratitis management.
Neurotrophic keratitis has been a lubrication, autologous serum, and amniotic membrane category with limited specific therapy. Cenegermin (recombinant nerve growth factor eye drops) has commercial maturity in moderate-to-severe neurotrophic keratitis, follow-on growth factor programs are in development, and structured corneal-specialty care pathways are formalising. The diagnostic-pathway question (neurotrophic keratitis is often missed because the corneal denervation reduces patient-reported symptoms) is the addressable-population enabler.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.